AyuVis Research
Fort Worth, US · Founded 2018 · Texas corporation
AyuVis develops novel small-molecule immunotherapies with a unique mode of action to fight inflammation and infection. Founded in 2014, the company focuses on drug discovery and clinical development in areas including neonatal immunology and infectious disease.
Founders & leadership
AyuVis Research was founded in 2018 by Suchismita Acharya and Suchi Acharya.
SA
Suchismita AcharyaFounder
SA
Suchi AcharyaFounder and CEO
DR
David RileyChief Medical Officer
DD
Dennis DeanHead of CMC
DC
Dale ChristensenDirector of Early Development
GA
Gagan AcharyaNamed on SEC filing
SM
Stella M RobertsonNamed on SEC filing
Reported raises · per SEC filings
Form D private placements$2M disclosed across 2 rounds · 2018–2019
▶$745KraisedOct 2019 · 17 investors · PharmaceuticalsRule 506(b)
▶$745KraisedOct 2019 · 17 investors · Pharmaceuticals
Rule 506(b)Officers, directors & promoters on the filing
- Gagan AcharyaDirector
- Stella M RobertsonDirector
- Dwight HortonExecutive Officer
- Beamon AgarwalExecutive Officer
- William Dennis DeanExecutive Officer
- Suchismita AcharyaExecutive Officer, Director
- Russell BromleyExecutive Officer
- Offering amount
- $750K
- Amount sold
- $745K
- Proceeds to insiders
- $60K
- First sale
- Apr 2019
- Incorporated
- Corporation, Texas, 2018
- Federal exemptions
- 06b
▶$1.3MraisedApr 2019 · 26 investors · PharmaceuticalsRule 506(b)
▶$1.3MraisedApr 2019 · 26 investors · Pharmaceuticals
Rule 506(b)Officers, directors & promoters on the filing
- Suchismita AcharyaExecutive Officer, Director
- Gagan AcharyaExecutive Officer, Director
- Stella M RobertsonDirector
- Offering amount
- $1.3M
- Amount sold
- $1.3M
- Proceeds to insiders
- $60K
- First sale
- Apr 2018
- Incorporated
- Corporation, Texas, 2018
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Non-dilutive funding · 2 SBIR/STTR awards
Federal grants — no equity taken| Agency | Phase | Year | Amount |
|---|---|---|---|
| National Institutes of Health (NIH)National Institutes of Health | Phase II | 2022 | $2M |
| National Institutes of Health (NIH)National Institutes of Health | Phase I | 2017 | $273.8K |
Source: SBIR.gov award data (U.S. Small Business Administration). SBIR/STTR awards are competitive federal R&D grants and contracts — non-dilutive capital alongside any venture rounds above.
Frequently asked questions
- What does AyuVis Research do?
- AyuVis develops novel small-molecule immunotherapies with a unique mode of action to fight inflammation and infection. Founded in 2014, the company focuses on drug discovery and clinical development in areas including neonatal immunology and infectious disease.
- Who founded AyuVis Research?
- AyuVis Research was founded by Suchismita Acharya, Suchi Acharya in 2018.
- How much funding has AyuVis Research raised?
- AyuVis Research has disclosed $2M raised across 2 rounds.
- Where is AyuVis Research headquartered?
- AyuVis Research is headquartered in Fort Worth, US.